Showing results (111-120 of 216) with videos related to
Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|May 15, 2012
National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in ChinaCong Xue, Zhihuang Hu, Wei Jiang, et al.International Journal of Cancer|April 19, 2018
Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER databaseHuaqiang Zhou, Yan Huang, Zeting Qiu, et al.Journal of Cancer Research and Clinical Oncology|September 29, 2020
Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancerWei Xian, Jiayi Shen, Huaqiang Zhou, et al.Lung Cancer (Amsterdam, Netherlands)|September 7, 2023
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)Yuanyuan Zhao, Yuxiang Ma, Yun Fan, et al.Frontiers in Immunology|December 30, 2024
<i>In vivo</i> programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor modelsShannon Argueta, Yuxiao Wang, Hongyun Zhao, et al.Annals of Translational Medicine|November 9, 2019
Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER databaseHuaqiang Zhou, Jiayi Shen, Yaxiong Zhang, et al.Journal of Thoracic Disease|November 21, 2013
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutationWenfeng Fang, Jianwei Zhang, Wenhua Liang, et al.Cancer Chemotherapy and Pharmacology|July 30, 2023
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction studyYuxiang Ma, Qun Chen, Yang Zhang, et al.Annals of Translational Medicine|January 6, 2022
Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapyWael Abdullah Sultan Ali, Pan Hui, Yuxiang Ma, et al.Medical Oncology (Northwood, London, England)|February 23, 2015
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinomaJianwei Zhang, Wenfeng Fang, Tao Qin, et al.Pageof 22